Trabeculectomy layer-by-layer

Article

Non-penetrating layer-by-layer trabeculectomy in ostias of Schlemm's canal produces a pronounced and sustained effect and can be applied successfully in patients with therapy resistant open angle glaucoma, according to Dr Dashevskiy from the Munich University of Technology, Germany.

Non-penetrating layer-by-layer trabeculectomy in ostias of Schlemm's canal produces a pronounced and sustained effect and can be applied successfully in patients with therapy resistant open angle glaucoma, according to Dr Dashevskiy from the Munich University of Technology, Germany.

The surgery was performed on 14 eyes of 10 patients (mean IOP 28.4±3.8 mmHg, mean age 70.3±5.4 years). Postoperative IOP, at one-year follow-up, was recorded at 13.1±2.3 mmHg. In each subject the hypotensive effect was absolute (without medications), whilst in five patients (36%), hyphaema appeared during surgery but dissolved in all cases between two and three days postoperatively.

Dr Dashevskiy believes that this novel surgical approach could represent a successful way of treating patients with therapy resistant glaucoma.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.